WallStreetZenWallStreetZen

NASDAQ: RNAZ
Transcode Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for RNAZ

Based on 1 analyst offering 12 month price targets for Transcode Therapeutics Inc

Min Forecast
$280.00+2,516.82%
Avg Forecast
$280.00+2,516.82%
Max Forecast
$280.00+2,516.82%

Should I buy or sell RNAZ stock?

Based on 1 analyst offering ratings for Transcode Therapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although RNAZ's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates RNAZ as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their RNAZ stock forecasts and price targets.

RNAZ stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-16

1 of 1

Forecast return on equity

Is RNAZ forecast to generate an efficient return?

Company
-75.95%
Industry
130.75%
Market
-52.16%
RNAZ's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is RNAZ forecast to generate an efficient return on assets?

Company
-56.48%
Industry
47.72%
RNAZ is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

RNAZ earnings per share forecast

What is RNAZ's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$45.65
Avg 2 year Forecast
-$8.96
Avg 3 year Forecast
-$6.72

RNAZ revenue forecast

What is RNAZ's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$500.0k
Avg 2 year Forecast
$9.9M
Avg 3 year Forecast
$27.8M

RNAZ vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RNAZ$10.70$280.00+2,516.82%Buy
APRE$1.54N/AN/A
CELZ$3.50N/AN/A
IBO$0.71N/AN/A
MTNB$1.83N/AN/A
View Top Biotech Stocks

Transcode Therapeutics Stock Forecast FAQ

Is Transcode Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: RNAZ) stock is to Buy RNAZ stock.

Out of 1 analyst, 0 (0%) are recommending RNAZ as a Strong Buy, 1 (100%) are recommending RNAZ as a Buy, 0 (0%) are recommending RNAZ as a Hold, 0 (0%) are recommending RNAZ as a Sell, and 0 (0%) are recommending RNAZ as a Strong Sell.

If you're new to stock investing, here's how to buy Transcode Therapeutics stock.

What is RNAZ's earnings growth forecast for 2025-2027?

(NASDAQ: RNAZ) Transcode Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.16%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.29%.

Transcode Therapeutics's earnings in 2025 is -$24,629,861.On average, 1 Wall Street analyst forecast RNAZ's earnings for 2025 to be -$38,053,877, with the lowest RNAZ earnings forecast at -$38,053,877, and the highest RNAZ earnings forecast at -$38,053,877. On average, 1 Wall Street analyst forecast RNAZ's earnings for 2026 to be -$7,470,717, with the lowest RNAZ earnings forecast at -$7,470,717, and the highest RNAZ earnings forecast at -$7,470,717.

In 2027, RNAZ is forecast to generate -$5,603,017 in earnings, with the lowest earnings forecast at -$5,603,017 and the highest earnings forecast at -$5,603,017.

What is RNAZ's revenue growth forecast for 2026-2029?

(NASDAQ: RNAZ) Transcode Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 86.2%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.83%.

Transcode Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast RNAZ's revenue for 2026 to be $416,842, with the lowest RNAZ revenue forecast at $416,842, and the highest RNAZ revenue forecast at $416,842. On average, 1 Wall Street analysts forecast RNAZ's revenue for 2028 to be $8,253,462, with the lowest RNAZ revenue forecast at $8,253,462, and the highest RNAZ revenue forecast at $8,253,462.

In 2029, RNAZ is forecast to generate $23,176,387 in revenue, with the lowest revenue forecast at $23,176,387 and the highest revenue forecast at $23,176,387.

What is RNAZ's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: RNAZ) forecast ROA is -56.48%, which is lower than the forecast US Biotechnology industry average of 47.72%.

What is RNAZ's Price Target?

According to 1 Wall Street analyst that have issued a 1 year RNAZ price target, the average RNAZ price target is $280.00, with the highest RNAZ stock price forecast at $280.00 and the lowest RNAZ stock price forecast at $280.00.

The Wall Street analyst predicted that Transcode Therapeutics's share price could reach $280.00 by Apr 16, 2026. The average Transcode Therapeutics stock price prediction forecasts a potential upside of 2,516.82% from the current RNAZ share price of $10.70.

What is RNAZ's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: RNAZ) Transcode Therapeutics's current Earnings Per Share (EPS) is -$812,663,111.90. On average, analysts forecast that RNAZ's EPS will be -$45.65 for 2025, with the lowest EPS forecast at -$45.65, and the highest EPS forecast at -$45.65. On average, analysts forecast that RNAZ's EPS will be -$8.96 for 2026, with the lowest EPS forecast at -$8.96, and the highest EPS forecast at -$8.96. In 2027, RNAZ's EPS is forecast to hit -$6.72 (min: -$6.72, max: -$6.72).

What is RNAZ's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: RNAZ) forecast ROE is -75.95%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.